Telomere shortening is the primary driver of replicative senescence. Senescent cells have the shortest telomeres in any given tissue. By selectively eliminating the shortest-telomere (most senescent) cell population, senolytics create a mathematical shift: the average telomere length of remaining cells increases. This "population enrichment" effect may partly explain the rejuvenation observed in animals after senolytic treatment.

Will senolytics improve my telomere test results?

Possibly. By eliminating the shortest-telomere senescent cells from circulating blood, senolytics may measurably improve average leukocyte telomere length in subsequent testing. Results depend on baseline senescent cell burden and testing methodology.

Should I combine senolytics with a telomerase activator?

The combination is mechanistically rational: senolytics clear cells with already-critical telomere shortening; telomerase activators slow shortening in remaining cells. No human trial data exists specifically for the combination.